Correction to: A novel SLC8A1/LINC01913 intergenic region-ALK fusion identified by NGS and validated by IHC and FISH in a stage IIB lung adenocarcinoma patient who remains relapse-free during the treatment of crizotinib: A case report.

Wang, Chunguang; Chen, Shu; He, Qianru; Sun, Tingting; Xu, Peiran

Wang, Chunguang; Chen, Shu; He, Qianru; Sun, Tingting; Xu, Peiran.

Affiliation

Wang C; Department of Thoracic Surgery, The Second Hospital of Jilin University, Changchun, China.
Chen S; The Medical Department, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, China.
He Q; The Medical Department, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, China.
Sun T; Nanjing Simcere Medical Laboratory Science Co., Ltd, Nanjing, China.
Xu P; The State Key Lab of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, China.

Invest New Drugs ; 40(6): 1357, 2022 Dec.

Article in En | MEDLINE | ID: mdl-35972630

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Invest New Drugs Year: 2022 Type: Article Affiliation country: China

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Invest New Drugs Year: 2022 Type: Article Affiliation country: China